Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_by |
healthcare professional
|
| gptkbp:approves |
gptkb:2011
gptkb:U._S._Food_and_Drug_Administration |
| gptkbp:chemical_formula |
C6464 H10000 N1716 O2000 S40
|
| gptkbp:class |
antineoplastic agent
|
| gptkbp:clinical_trial |
Phase 2
AETHERA AVD regimen BRIDGE study ECHELON-1 ECHELON-2 |
| gptkbp:clinical_use |
monotherapy or in combination with chemotherapy
|
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to brentuximab vedotin |
| gptkbp:developed_by |
gptkb:Seattle_Genetics
|
| gptkbp:dosage_form |
every 2 weeks
|
| gptkbp:drug_interactions |
may interact with other immunosuppressants
|
| gptkbp:effective_date |
August 19, 2011
|
| gptkbp:form |
injection
|
| gptkbp:formulation |
lyophilized powder for reconstitution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Adcetris
|
| gptkbp:indication |
relapsed or refractory systemic anaplastic large cell lymphoma
relapsed or refractory Hodgkin lymphoma |
| gptkbp:ingredients |
gptkb:brentuximab_vedotin
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count neurological status |
| gptkbp:launch_date |
gptkb:2011
|
| gptkbp:manufacturer |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:marketed_as |
gptkb:brentuximab_vedotin
|
| gptkbp:mechanism_of_action |
CD30-targeting antibody-drug conjugate
|
| gptkbp:packaging |
single-use vial
|
| gptkbp:patient_population |
adults and children over 2 years old
|
| gptkbp:pharmacokinetics |
antibody-drug conjugate mechanism
half-life approximately 4 days |
| gptkbp:recommissioned |
requires sterile water for injection
|
| gptkbp:research_areas |
oncology
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
fatigue
nausea liver toxicity peripheral neuropathy increased risk of infections infusion reactions neutropenia pulmonary toxicity tumor lysis syndrome |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
gptkb:CD30
|
| gptkbp:trade |
gptkb:Adcetris
|
| gptkbp:used_for |
treatment of Hodgkin lymphoma
treatment of systemic anaplastic large cell lymphoma |
| gptkbp:weight |
approximately 150 k Da
|
| gptkbp:bfsParent |
gptkb:Brentuximab_vedotin
|
| gptkbp:bfsLayer |
6
|